A detailed history of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main transactions in Exelixis, Inc. stock. As of the latest transaction made, Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main holds 9,357 shares of EXEL stock, worth $333,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,357
Previous 230,980 95.95%
Holding current value
$333,202
Previous $5.19 Million 95.34%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $4.87 Million - $6.12 Million
-221,623 Reduced 95.95%
9,357 $242,000
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $1.17 Million - $1.36 Million
57,370 Added 33.05%
230,980 $5.19 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $3.21 Million - $3.81 Million
159,249 Added 1108.9%
173,610 $4.12 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $201,143 - $252,134
-10,449 Reduced 42.12%
14,361 $344,000
Q2 2023

May 17, 2024

SELL
$18.17 - $20.48 $2.7 Million - $3.05 Million
-148,800 Reduced 85.71%
24,810 $474,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $791,267 - $891,863
-43,548 Reduced 63.71%
24,810 $474,000
Q1 2023

May 17, 2024

SELL
$16.3 - $19.41 $1.13 Million - $1.35 Million
-69,580 Reduced 50.44%
68,358 $1.33 Million
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $1.13 Million - $1.35 Million
-69,580 Reduced 50.44%
68,358 $1.33 Million
Q4 2022

May 17, 2024

SELL
$14.96 - $17.39 $533,653 - $620,336
-35,672 Reduced 20.55%
137,938 $2.21 Million
Q4 2022

Feb 14, 2023

SELL
$14.96 - $17.39 $12,970 - $15,077
-867 Reduced 0.62%
137,938 $2.21 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $2.08 Million - $2.96 Million
132,805 Added 2213.42%
138,805 $2.18 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $104,640 - $138,960
6,000 New
6,000 $125,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Portfolio

Follow Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.